CrisprBits Raises $3 Million to Expand CRISPR Biotech Platforms

25

CrisprBits Raises $3 Million to Expand CRISPR biotech platforms in a fresh Pre-Series A funding round that values the Bengaluru startup at $12 million. The investment was led by Spectrum Impact, the family office of Rajendra Gogri of Aarti Industries, along with participation from existing and new investors including VJ Technologies Group and the promoter family of HBL Engineering. The company plans to use the fresh capital to accelerate commercialization of PathCrisp, its CRISPR-powered molecular diagnostics platform, and expand manufacturing capabilities for tests in human health, food safety and animal health. The funding will also push development of a next-generation CRISPR strain engineering system aimed at improving industrial biofuel production, a space that is growing rapidly as the world searches for climate-friendly energy solutions.

CrisprBits was founded by a team of BITS Pilani alumni with deep scientific and commercial experience in gene editing, molecular diagnostics, synthetic biology, and computational research. The company runs a large CRISPR research and prototyping facility in Bengaluru that enables it to move fast across R&D, product validation, and clinical collaborations. Its platforms include PathCrisp, EdiCrisp, and CurieCrisp, each focused on different real-world applications such as rapid detection of antimicrobial resistance, affordable genetic diagnostics and precision strain engineering for biomanufacturing. With the new funding, the startup plans to enter global markets across Africa and Latin America, regions where low-cost and field-deployable diagnostic solutions are increasingly needed. The development aligns with large industry tailwinds, including strong national support for synthetic biology, increasing awareness of rare genetic diseases and expanding adoption of CRISPR-based diagnostics worldwide.

As the startup ecosystem matures, CrisprBits Raises $3 Million to Expand CRISPR research, production, and global commercialization while building a robust business model backed by patient capital. The company aims to democratize access to advanced biotechnology, positioning itself as one of India’s most important emerging enterprises in the synthetic biology revolution.

1. Introduction

CrisprBits Raises $3 Million to Expand CRISPR capacity in a major Pre-Series A funding round, signaling rising investor confidence in India’s biotechnology sector. The Bengaluru startup is among the first Indian companies commercializing CRISPR-based molecular diagnostics and precision strain engineering platforms. The fresh investment aims to scale manufacturing, accelerate product commercialization and enable global expansion.

1.1 Background of the Startup

Founded by experienced scientists and industry leaders, CrisprBits began with a mission to bring advanced gene editing and molecular diagnostics to hospitals, farms and industrial facilities. While the global biotech landscape has been dominated by US and European companies, CrisprBits is part of a new wave of Indian startups building world-class research infrastructure.

1.2 Founders and Leadership

1. Vijay Chandru
2. Sunil Arora
3. Prof. Rajeev Kohli
4. Bharat Jobanputra
5. Aditya Sarda

Each founder brings deep background in computational biology, genomics, business strategy and biotechnology commercialization. Together, they shaped a company able to translate complex research into affordable, scalable products.

1.3 What the Company Does

The company develops CRISPR-powered platforms for diagnostics, precision genome modification and sustainable biomanufacturing. Its technology is designed to give hospitals, laboratories and industries faster genetic analysis, improved process efficiency and field-deployable testing.

2. CrisprBits Working Model

The core engine of the company is its proprietary CRISPR systems integrated with biochemical workflows, imaging analytics, and automated laboratory processes. The company’s approach begins with problem-specific CRISPR constructs designed to detect genetic signatures or modify them in a targeted way.

2.1 Diagnostic Workflow

1. Sample collection from patient, food or animal.
2. Minimal sample preparation.
3. CRISPR recognition of target sequences.
4. Rapid optical or biochemical output readout.
5. Result interpretation within 2.5 hours.

This approach enables high-accuracy molecular testing in the field and in clinical settings without large laboratory infrastructure.

2.2 Genome Editing Model

The EdiCrisp platform provides a complete pipeline from design of CRISPR constructs to cellular testing. Industries can use it to create improved microbial strains for biomaterials, fuels and pharmaceutical products.

2.3 Strain Engineering Explained

The strain engineering system improves industrial organisms through targeted genetic modifications, resulting in increased yield, reduced waste and lower production cost. The first application is optimization of biofuel pathways.

3. Revenue Model

The company uses a multi-stream commercial framework built around product sales, platform licensing, contract research and enterprise partnerships. By maintaining profit orientation from the start, the firm avoided excessive equity dilution and aligned with investors seeking long-term growth.

3.1 Revenue Sources

1. Diagnostic product sales.
2. Licensing of CRISPR platforms.
3. Custom gene editing development.
4. Joint research collaborations.
5. Industrial strain engineering contracts.

3.2 Market Monetization Approach

The company focuses on high-value clinical and industrial applications where precision biotechnology offers measurable economic returns such as faster throughput, better diagnostics and better yields in biomanufacturing systems.

4. Funding and Investment

CrisprBits Raises $3 Million to Expand CRISPR technology across diagnostics and synthetic biology. The funding round was led by Spectrum Impact, alongside existing investors and new participants. The valuation stands at $12 million.

4.1 Use of Funds

1. Scaling PathCrisp manufacturing.
2. Commercial rollout of diagnostic kits.
3. Building an AI-enabled strain engineering platform.
4. International expansion into Africa and Latin America.
5. Increasing production capacity at the Bengaluru facility.

4.2 Investor Sentiment

Investors believe the company sits at the intersection of advanced biology, process engineering and affordable healthcare. The leadership team has a track record of delivering commercial results while working in a research-heavy industry.

4.3 Why Investors See Potential

Global demand for molecular diagnostics and synthetic biology solutions is growing due to an increase in antimicrobial resistance, rising incidence of genetic disorders and industrial demand for sustainable production methods. With these trends converging, CrisprBits is positioned well in the competition.

5. Products and Platforms

The company currently operates three major platforms.

5.1 PathCrisp

A field-deployable diagnostics platform providing genetic detection in less than 2.5 hours. Its product lineup includes:

1. Typhoid detection
2. Sickle cell diagnosis
3. AMR detection
4. Foodborne pathogen tests
5. Animal disease surveillance systems

5.2 EdiCrisp

A gene editing platform that enables gene knockouts, insertions and strain improvements. It is used in mammalian cells, bacteria, yeast and plant systems.

5.3 CurieCrisp

A preclinical therapeutics platform integrating patient-specific cell models and AI analytics to accelerate drug discovery while reducing development cost.

6. Industry Problems the Startup Solves

The company addresses several urgent industry challenges.

6.1 Delayed Diagnostics

Traditional PCR and laboratory testing often take two to five days. Rapid CRISPR-based detection can bring testing timelines below three hours, enabling timely treatment and improved public health outcomes.

6.2 High-Cost Genetic Tools

Import-dependent systems make gene testing expensive in developing markets. Local innovation lowers costs and improves accessibility.

6.3 Limited Rare Disease Research Capacity

Many disorders lack reliable models. The CurieCrisp platform helps close this gap through advanced iPSC and AI-powered analysis.

6.4 Industrial Inefficiencies

Biofuel and biochemical production often suffer high cost-to-yield ratios. Precision strain engineering improves efficiency, reducing the environmental footprint.

7. Industry Growth and Market Landscape

The funding arrives at a time when biotechnology is expanding rapidly in India. Government support, academic research leadership and large pharmaceutical demand are fueling new business creation.

7.1 Market Growth Context

India now has over 10,000 biotech startups, compared to about 50 a decade ago. The national government is pushing to reach a $300 billion bioeconomy by 2030, according to industry briefings.

7.2 Global Trends

Worldwide, CRISPR diagnostics and synthetic biology are becoming mainstream due to fast innovation cycles and improved research understanding. Companies that can commercialize real-world applications are positioned to benefit.

8. Competitive landscape

CrisprBits operates in a field that is fiercely competitive and full of heavyweight rivals. For instance, global biotech giants like Mammoth Biosciences, Sherlock Biosciences, Caribou Biosciences, and Editas Medicine have raised vast amounts of capital and already have deep research pipelines. Many of these firms are backed by Nobel laureates, major universities, and large pharma partners.

In India itself, the competition is thinner but growing. Several diagnostics and biotech players are experimenting with CRISPR platforms for infectious disease testing, agricultural genome engineering, and personalized medicine. However, CrisprBits stands out because it has built a clinically validated genome editing system and filed multiple patents early. As a result, the company now has a stronger competitive position and greater defensibility in the market. Additionally, this gives the company a chance to lead the Indian segment while developing differentiated intellectual property that global players cannot easily replicate.

9. Patent dispute context

CRISPR technology has a long and complicated history of patent wars. The foundational legal battle between the Jennifer Doudna and Emmanuelle Charpentier group versus the Feng Zhang group lasted years, with different regions awarding different rights. Anyone building commercial CRISPR products must avoid infringement or license core patents.

CrisprBits appears to have structured its research approach to build new molecular tools rather than merely implementing previously patented components. This reduces dependency on contested IP and gives the startup breathing room in global markets. With its own patents already filed for diagnostics, reagent validation, and computational design methods, CrisprBits is taking the protection of its inventions seriously at an early stage.

10. Challenges and industry barriers

Deep biotech is not easy. CrisprBits must navigate several real hurdles:

• Lengthy regulatory approvals that can take years in human use cases.
• The need for heavy R&D expenditure, unlike software startups that can scale quickly with low burn.
• Manufacturing consistency, since wet lab products can have batch variability that affects reliability.
• Talent scarcity, as scientists with experience in CRISPR platforms and wet lab product engineering are limited and expensive worldwide.
• Market education, because doctors, labs, researchers, and patients still need awareness around CRISPR-based diagnostics and safety.

Despite this, the firm’s traction in clinical validation and strong seed funding allows it to continue product development while building partnerships across labs and hospitals.

11. Learning for founders

There are several takeaways from CrisprBits that any startup founder can appreciate:

• Don’t build in stealth for too long. Build, test, validate, and bring your product into real markets early.
• Patents matter more in deep tech than brand building. If you invent something, protect it before scaling.
• Government partnerships are powerful in regulated industries. Collaboration with institutions like BIRAC opened doors that private networks alone cannot.
• Move slowly but with discipline. Biotech does not reward “launch fast and fix later.” Safety, accuracy, and reliability matter more than speed.
• A strong founder-market fit matters. The CrisprBits leadership team had prior experience in genomic science and product development, which allowed them to move faster than inexperienced competitors.

About FoundLanes

At foundlanes.com is a dedicated platform chronicling the evolution of the startup ecosystem across India and the globe. CrisprBits raising 3 million dollars is a signal of India’s maturity in biotechnology. The last decade belonged to fintech, SaaS, and D2C. The coming decade may belong to genomics, lab automation, AI-driven drug discovery, and personalized medicine. With India already having one of the largest patient data pools on the planet, startups that can turn biological data into real medical breakthroughs will have an edge.